|
AU2011217848B8
(en)
|
2010-02-18 |
2015-09-24 |
The Regents Of The University Of California |
Integrin aVB8 neutralizing antibody
|
|
US20140079722A1
(en)
*
|
2011-03-09 |
2014-03-20 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
WO2013023162A2
(en)
*
|
2011-08-10 |
2013-02-14 |
Genus Oncology, Llc |
Anti-muc1 antibodies for cancer diagnostics
|
|
KR102010098B1
(ko)
*
|
2011-08-17 |
2019-08-13 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
인테그린 알파-v 베타-8에 결합하는 항체
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CN102786595B
(zh)
*
|
2012-08-03 |
2014-04-23 |
无锡傲锐东源生物科技有限公司 |
抗cd5蛋白单克隆抗体及其用途
|
|
CN105188749B
(zh)
|
2012-12-21 |
2017-12-19 |
西雅图基因公司 |
抗ntb‑a抗体及相关组合物和方法
|
|
HK1210713A1
(en)
*
|
2012-12-27 |
2016-05-06 |
Sanofi |
Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
|
|
KR102211837B1
(ko)
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
AU2015218909A1
(en)
*
|
2014-02-19 |
2016-08-04 |
Emergent Biosolutions Canada Inc. |
Marburg monoclonal antibodies
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
US10786549B2
(en)
|
2015-04-23 |
2020-09-29 |
Baylor College Of Medicine |
CD5 chimeric antigen receptor for adoptive T cell therapy
|
|
US11369663B2
(en)
*
|
2016-06-07 |
2022-06-28 |
Washington University |
Detection of CD5 and methods and compositions for modulating CD5
|
|
CN109715663B
(zh)
|
2016-06-28 |
2022-11-25 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
|
WO2018017864A2
(en)
*
|
2016-07-20 |
2018-01-25 |
Oncomed Pharmaceuticals, Inc. |
Pvrig-binding agents and uses thereof
|
|
CA3037144A1
(en)
*
|
2016-09-16 |
2018-03-22 |
Shanghai Henlius Biotech, Inc. |
Anti-pd-1 antibodies
|
|
US20180128545A1
(en)
|
2016-11-08 |
2018-05-10 |
Berry Metal Company |
Modular furnace cooling wall
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
CN119857155A
(zh)
|
2017-11-29 |
2025-04-22 |
海德堡医药研究有限责任公司 |
用于耗尽cd5+细胞的组合物和方法
|
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
US11435351B2
(en)
|
2018-04-18 |
2022-09-06 |
Biomadison, Inc. |
Methods for determining vaccine potency
|
|
WO2020084034A1
(en)
|
2018-10-26 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Multispecific antibody screening method using recombinase mediated cassette exchange
|
|
WO2020097193A1
(en)
|
2018-11-06 |
2020-05-14 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
CN113454117B
(zh)
|
2018-12-19 |
2025-07-04 |
宾夕法尼亚大学董事会 |
Cd2/5/7敲除抗-cd2/5/7嵌合抗原受体t细胞针对t细胞淋巴瘤和白血病的用途
|
|
US12384811B2
(en)
|
2019-04-05 |
2025-08-12 |
Academia Sinica |
Sialidase-resistant saccharide and method of making and using the same
|
|
NZ781538A
(en)
|
2019-04-24 |
2025-12-19 |
Heidelberg Pharma Res Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
|
US11026973B2
(en)
|
2019-04-30 |
2021-06-08 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
CN114981409A
(zh)
|
2019-09-03 |
2022-08-30 |
美洛德生物医药公司 |
用于基因组整合的方法和组合物
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
TWI870591B
(zh)
|
2020-05-08 |
2025-01-21 |
中央研究院 |
嵌合流感疫苗
|
|
WO2021231982A1
(en)
*
|
2020-05-14 |
2021-11-18 |
City Of Hope |
Smc1a antibodies and uses thereof
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
EP3915641A1
(en)
*
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5 antibodies and methods of use thereof
|
|
JP2023538108A
(ja)
*
|
2020-08-21 |
2023-09-06 |
シティ・オブ・ホープ |
抗ｃｄ５抗体組成物及びその使用
|
|
WO2022056459A1
(en)
|
2020-09-14 |
2022-03-17 |
Vor Biopharma, Inc. |
Compositions and methods for cd5 modification
|
|
EP4240367A4
(en)
|
2020-11-04 |
2024-10-16 |
Myeloid Therapeutics, Inc. |
MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US20220144956A1
(en)
*
|
2020-11-06 |
2022-05-12 |
Xencor, Inc. |
HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
|
|
CN116801905A
(zh)
*
|
2020-12-17 |
2023-09-22 |
先声再明医药有限公司 |
Cd5抗体及其应用
|
|
EP4279508A4
(en)
*
|
2021-01-12 |
2024-12-04 |
Nanjing Iaso Biotechnology Co., Ltd. |
Cd5-targeting fully humanized antibody
|
|
EP4288455A1
(en)
|
2021-02-03 |
2023-12-13 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
BR112023000666A2
(pt)
|
2021-04-12 |
2023-10-24 |
Academia Sinica |
Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica
|
|
KR102831183B1
(ko)
*
|
2021-04-29 |
2025-07-09 |
한국생명공학연구원 |
신규한 항-cd5 키메릭 항원 수용체 및 이를 발현하는 면역세포
|
|
BR112023023642A2
(pt)
|
2021-05-11 |
2024-01-30 |
Myeloid Therapeutics Inc |
Métodos e composições para integração genômica
|
|
CN113105547B
(zh)
*
|
2021-05-18 |
2022-04-08 |
福州迈新生物技术开发有限公司 |
抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用
|
|
TW202334429A
(zh)
|
2021-10-01 |
2023-09-01 |
中央研究院 |
Sars-cov-2棘蛋白特異性抗體及其用途
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
US12077597B2
(en)
|
2021-11-24 |
2024-09-03 |
International-Drug-Development-Biotech |
Anti-CD5 antibodies and methods of use thereof
|
|
WO2023129928A2
(en)
*
|
2021-12-27 |
2023-07-06 |
Academia Sinica |
Antibody specific to spike protein of sars-cov-2 and uses thereof
|
|
WO2024039683A1
(en)
*
|
2022-08-15 |
2024-02-22 |
Myeloid Therapeutics, Inc. |
Compositions and methods for conditioning patients for cell therapy
|
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
US12318485B2
(en)
|
2023-04-08 |
2025-06-03 |
Rock Biomedical, Inc. |
Methods and compositions for targeted delivery by polymersomes
|
|
AU2024252371B2
(en)
|
2023-04-08 |
2026-02-12 |
Rock Biomedical Inc. |
Methods and compositions for dendritic cell targeting nano-delivery
|
|
WO2024238734A2
(en)
|
2023-05-17 |
2024-11-21 |
Rock Biomedical Inc. |
Mgat1 deficient cells and uses thereof
|
|
AU2024279278A1
(en)
|
2023-05-31 |
2025-12-18 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
CN121712526A
(zh)
*
|
2023-06-13 |
2026-03-20 |
辛瑟斯治疗股份有限公司 |
抗cd5抗体及其用途
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025220805A1
(ko)
*
|
2024-04-18 |
2025-10-23 |
주식회사 큐로셀 |
신규한 항-cd5 키메릭 항원 수용체 및 이의 용도
|